(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual revenue growth rate of -25.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Orchestra Biomed Holdings's revenue in 2026 is $31,976,000.On average, 9 Wall Street analysts forecast OBIO's revenue for 2026 to be $25,544,826, with the lowest OBIO revenue forecast at $23,561,179, and the highest OBIO revenue forecast at $31,555,151. On average, 9 Wall Street analysts forecast OBIO's revenue for 2027 to be $38,623,504, with the lowest OBIO revenue forecast at $23,561,179, and the highest OBIO revenue forecast at $80,781,186.
In 2028, OBIO is forecast to generate $979,832,509 in revenue, with the lowest revenue forecast at $318,075,919 and the highest revenue forecast at $2,323,120,249.